RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

BRAF inhibitors are commonly used in targeted therapies for melanoma patients harboring BRAF(V600E) mutant. Despite the benefit of vemurafenib therapy, acquired resistance during or after treatment remains a major obstacle in BRAF(V600E) mutant melanoma. Here we found that RSK2 is overexpressed in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hai-Zhou, Li, Lan-Ya, Jiang, Shi-Long, Li, Yi-Zhi, Shi, Xiao-Mei, Sun, Xin-Yuan, Li, Zhuo, Cheng, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541206/
https://www.ncbi.nlm.nih.gov/pubmed/36210843
http://dx.doi.org/10.3389/fphar.2022.950571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541206/
https://www.ncbi.nlm.nih.gov/pubmed/36210843
http://dx.doi.org/10.3389/fphar.2022.950571

Ejemplares similares